Myeloproliferative Neoplasm, Unclassifiable Clinical Trial
Official title:
A Feasibility Study of 12 Weeks of Smartphone-based Health Education Podcasts in Myeloproliferative Neoplasm Patients
Enrolled MPN patients will participate in a podcast intervention via a smartphone app. They will listen to 60 minutes per week of podcasts through this app, which consist of cancer-related health education material. Participants have the option to listen to additional podcasts beyond the 60-minute weekly prescription if they desire. Participation will be tracked through self-report logs. In addition, questionnaires will be administered at baseline, midpoint (week 6), and post-intervention (week 12), which ask about demographics, health information, and satisfaction. The hypothesis is that the smartphone app is feasible for delivering home-based health education podcasts to MPN patients.
Interested patients will complete an eligibility screening using a REDCap link (see
eligibility survey). The eligibility screening takes 5-10 minutes to complete.
If ineligible, the participant will be sent an email notification (see study protocol).
If eligible, the potential participant will be sent a link to a video containing a detailed
overview of the informed consent as well as a link to sign the informed consent. There will
be a place for the participant to type in their electronic signature, which will constitute
their consent to participate in the study (see informed consent). After signing the informed
consent, participants will be sent an additional email with their study start date, which
will fall on the next Monday after signing the informed consent so that all participants
begin participating on a Monday. On the day of their study start date, participants will be
sent a welcome email as well as a link to complete the baseline self-report measure (listed
below) via REDCap.
Within the welcome email, there will be step-by-step instructions for accessing the podcast
intervention via a smartphone app. Participants will be asked to view 60 minutes per week of
podcasts through a smartphone app. The podcast videos will contain general cancer-related
health education material. A total of 60 minutes per week will be prescribed, however,
participants will have the ability to view additional videos each week. Furthermore,
participants will also track their podcast video viewing each week in a weekly log (see
weekly log) by recording each time they view a video, the video that they viewed, and how
long they viewed the video.
The investigators will use self-report questionnaires at baseline (week 0), mid-point (week
6), and post-intervention (week 12) administered via REDCap (see baseline, mid-point, and
post-intervention surveys). Demographics data and MPN-related health information will be
collected at baseline and satisfaction-related data will be collected within the
post-intervention questionnaire. Feasibility measures will include acceptability, demand, and
practicality.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05326919 -
The Patient Cohort of the National Center for Precision Medicine in Leukemia
|
||
| Recruiting |
NCT04282187 -
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
|
Phase 2 | |
| Completed |
NCT03566446 -
CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms
|
Phase 1 | |
| Completed |
NCT05825326 -
Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador
|
||
| Active, not recruiting |
NCT03862157 -
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 1/Phase 2 |